Randomized phase II study of Erlotinib vs. S-1 for non-small lung cancer after failure of two or three prior

Trial Profile

Randomized phase II study of Erlotinib vs. S-1 for non-small lung cancer after failure of two or three prior

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Erlotinib (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms HOT1002
  • Most Recent Events

    • 18 Oct 2017 Results comparing clinical outcomes between erlotinib and S-1 as third or fourth line therapy, presented at the 18th World Conference on Lung Cancer.
    • 29 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top